TransgeneFRA:TGNA -0.14%47 OCF Margin % is -6,920.29% as of Dec. 2025. GuruFocus rates FRA:TGNA with a GF Score™ of 47/100 and a GF Value™ of €0.51 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 957 Biotechnology companies, Transgene ranks worse than 93% on this metric.
The historical rank and industry rank for Transgene's OCF Margin % or its related term are showing as below:
FRA:TGNA'
s OCF Margin % Range Over the Past 10 Years
Min: -7670.36 Med: -1558.34 Max: -259.27
Current: -7560.41
During the past 13 years, the highest OCF Margin % of Transgene was -259.27%. The lowest was -7670.36%. And the median was -1558.34%.
FRA:TGNA's OCF Margin % is ranked worse than 93% of 957
companies
in the Biotechnology industry
Industry Median: -66.52
vs FRA:TGNA: -7560.41
Transgene OCF Margin % Related Terms
Transgene OCF Margin % Historical Data
* Premium members only.
The historical data trend for Transgene's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TGNA vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Transgene's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgene OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgene's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Transgene's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgene (FRA:TGNA) has a OCF Margin % of -6,920.29% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Transgene and its competitors. According to the industry distribution chart, Transgene ranks #890 out of 957 companies in the Biotechnology industry, placing it in the top 93%.
Is Transgene's OCF Margin % too high?
Transgene's current OCF Margin % is -6,920.29%. Based on the distribution chart, Transgene ranks #890 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transgene has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transgene's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgene ranks #890 out of 957 companies for OCF Margin %. This places Transgene in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Transgene and its competitors. Transgene's current OCF Margin % is -6,920.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene stock overvalued right now?
Based on GuruFocus' analysis, Transgene (FRA:TGNA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.51, compared to a current price of €0.70 — trading 37.8% above its estimated fair value. The current OCF Margin % is -6,920.29%. Transgene's overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Transgene (FRA:TGNA), the current OCF Margin % is -6,920.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgene (FRA:TGNA) Overvalued in 2026?
Based on GuruFocus' analysis, Transgene stock appears to be overvalued.
The current stock price of €0.70 is trading 37.8% above its estimated GF Value™ of €0.51.
GuruFocus considers Transgene to be Significantly Overvalued.
Key valuation signals for FRA:TGNA:
OCF Margin %: -6,920.29%
GF Value™: €0.51 vs. price of €0.70 (37.8% above fair value)
No single metric tells the full story. See the FRA:TGNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
47GF Score
Get the complete analysis for FRA:TGNA
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TGNA has been successfully added to your 
